“India is critical in shaping Lupin’s growth story going forward. This acquisition strengthens our position in the Indian market, where we have already established ourselves as a leading provider of quality pharmaceuticals and a trusted partner.” - Nilesh Gupta, MD, Lupin
April 2022 : Global pharma major Lupin Limited (Lupin) announced today the completion of the acquisition of a portfolio of brands from Anglo-French Drugs & Industries Limited (AFDIL) and its Associates.
The acquisition will strengthen Lupin’s India Formulation business by adding a fast-growing portfolio of vitamins, minerals, supplements and neurological products. The acquisition of the AFDIL brands takes Lupin further in shaping its portfolio to emerge as a leading pharmaceutical company in India.
“India is critical in shaping Lupin’s growth story going forward. This acquisition strengthens our position in the Indian market, where we have already established ourselves as a leading provider of quality pharmaceuticals and a trusted partner. With this portfolio, Lupin will have a stronger market presence, providing healthcare professionals and patients with a more meaningful and comprehensive product offering,” said Nilesh Gupta, Managing Director, Lupin. “The portfolio sold to Lupin was birthed by Anglo-French, and now, through this divestiture, we are confident that these brands will scale to a significant size and have a large impact on the health and well-being of the Indian population. We are confident in Lupin's ability to enhance the value of our portfolio of brands,” said Abhay Kanoria, Chairman & MD, AFDIL.
Shailesh Gadre, Founder of GCV Life was the exclusive advisor for the transaction.
About Lupin: Lupin is an innovation-led transnational pharmaceutical company headquartered in Mumbai, India. The Company develops and commercializes a wide range of branded and generic formulations, biotechnology products and APIs in over 100 markets in the U.S., India, South Africa and across Asia Pacific (APAC), Latin America (LATAM), Europe and Middle-East regions. The Company enjoys leadership position in the cardiovascular, anti-diabetic, and respiratory segments and has significant presence in the anti-infective, gastro-intestinal (GI), central nervous system (CNS) and women’s health areas. Lupin is the third largest pharmaceutical company in the U.S. by prescriptions. The company invested 9.6% of its revenue on research and development in FY21. Lupin has 15 manufacturing sites, 7 research centres, more than 20,000 professionals working globally, and has been consistently recognized as a ‘Great Place to Work’ in the Biotechnology & Pharmaceuticals sector.
About Anglo-French Drugs & Industries Limited (AFDIL): Anglo-French Drugs and Industries Ltd. began as an importer of medicines in 1923, but has built an impressive identity for itself with over 300 products selling across the world. The company has market leading brands in nutraceuticals, CNS, skin and respiratory segments. It believes its biggest strength is its family of nearly 1000 people, who work diligently to serve over 65,000 doctors, 50,000 chemists and all other affiliated parties. The company is headquartered in Bengaluru, India and has its manufacturing unit there as well. AFDIL has won multiple HR and marketing awards, and its RnD lab has been recognised in the Industry as well.
NEWSLETTER
TRENDING ON PRO MFG
MORE FROM THE SECTION
